Management of Hepatic Encephalopathy

General Management Principles

• The American Association for the Study of Liver Diseases recommends that all patients with overt hepatic encephalopathy require immediate treatment with a four-pronged approach: stabilization of altered consciousness, exclusion of alternative causes, identification and correction of precipitating factors, and empirical HE treatment with lactulose 1, 2
• Identifying and correcting precipitating factors resolves HE in nearly 90% of patients and is the cornerstone of management 1, 2, 3

Grades I-II Management

• Manage patients on a medicine ward with frequent mental status checks, though ICU is preferable 4, 5
• Transfer to ICU immediately if level of consciousness declines 5
• Avoid sedatives as they worsen encephalopathy and have delayed clearance in liver failure 5
• The European Association for the Study of the Liver suggests that grade I patients have mild alterations in consciousness, subtle personality changes, decreased attention, sleep disturbances, irritability or apathy, difficulty with complex cognitive tasks 5
• Grade II patients have mild disorientation, pronounced lethargy, inappropriate behavior, asterixis, dysarthric or slow speech 5

Grades III-IV Management

• Patients with grade III-IV encephalopathy require ICU admission with intensive monitoring 1, 2
• Intubate the trachea to protect airway 4
• Elevate head of bed 4
• Minimize stimulation 4
• Cerebral edema occurs in 25-35% of grade III patients and 65-75% of grade IV patients 4

Pharmacologic Treatment

• Start lactulose 25 mL orally every 12 hours, titrated to achieve 2-3 soft bowel movements daily 3
• Achieves clinical response in approximately 75% of patients 3
• Add rifaximin 550 mg twice daily if patient has recurrent episodes despite lactulose 3
• Reduces HE recurrence risk by 58% when added to lactulose 3

Secondary Prophylaxis

• Secondary prophylaxis with lactulose is mandatory after the first episode of overt HE 1, 2, 5, 3
• Continue lactulose indefinitely, titrated to 2-3 soft stools daily 3
• Add rifaximin 550 mg twice daily after the second episode or if recurrence occurs despite lactulose 3

Nutritional Management

• Do not restrict protein—this worsens malnutrition and sarcopenia, which are risk factors for HE 3
• Provide moderate hyperalimentation with small, frequent meals throughout the day 5, 3
• Include a late-night snack 5, 3
• Avoid fasting periods which worsen HE 3

Liver Transplantation Evaluation

• Evaluate for liver transplantation after the first episode of overt HE 5
• Recurrent intractable overt HE with liver failure is an indication for liver transplantation 1, 2, 5

Critical Pitfalls to Avoid

• Failing to systematically search for precipitating factors, which cause 90% of cases 5, 3
• Not titrating lactulose adequately to achieve 2-3 stools per day 5, 3
• Confusing HE with other causes of altered mental status 5, 3
• Not initiating secondary prophylaxis after the first episode 5, 3
• Relying exclusively on ammonia levels for diagnosis—they lack diagnostic, staging, or prognostic value 2, 5
• Restricting protein intake, which worsens outcomes 3

Hepatic Encephalopathy Management

Pharmacologic Treatment

• Oral branched-chain amino acids (BCAAs) can be used as an alternative or additional agent for patients nonresponsive to conventional therapy, according to the European Association for the Study of the Liver 6
• IV L-ornithine L-aspartate (LOLA) can be used as an alternative or additional agent for patients nonresponsive to conventional therapy, as recommended by the European Association for the Study of the Liver 6
• Neomycin and metronidazole are alternative choices, though long-term use carries ototoxicity, nephrotoxicity, and neurotoxicity risks, as noted by the American Association for the Study of Liver Diseases 6

Management of Precipitating Factors in Hepatic Encephalopathy

Epidemiology and Clinical Impact

• Identification and correction of precipitating factors is the cornerstone of hepatic encephalopathy (HE) management; such factors are present in 80‑90 % of HE episodes, and their correction alone resolves HE in ≈ 90 % of patients (Clinical and Molecular Hepatology, 2020) 7.

Diagnostic and Therapeutic Approach

• The following table summarizes the most common precipitating factors, recommended diagnostic evaluations, and first‑line treatments (Clinical and Molecular Hepatology, 2020) 7:

• Prompt evaluation for these factors and initiation of the listed interventions should be performed in all patients presenting with overt HE (Clinical and Molecular Hepatology, 2020) 7.

Management of Overt Hepatic Encephalopathy

Initial Assessment and Structured Approach

• All patients with overt hepatic encephalopathy should immediately undergo a four‑pronged approach: (1) stabilize consciousness and protect the airway, (2) exclude alternative causes such as intracranial hemorrhage, infection, or metabolic derangements, (3) identify and correct precipitating factors (present in 80‑90 % of episodes), and (4) start empirical lactulose without delay. [8][9]10

Identification and Correction of Precipitating Factors

• Systematic search for precipitating factors is essential because correcting them alone resolves hepatic encephalopathy in ≈ 90 % of patients. [9][10]11

Acute Pharmacologic Therapy

• Lactulose 25 mL orally every 12 h is the initial dose; it must be titrated to produce 2–3 soft bowel movements per day. Underdosing leads to treatment failure, while overdosing can cause dehydration, hypernatremia, aspiration risk, and severe perianal irritation. The target is 2–3 stools, not diarrhea. [8][9]

Secondary Prophylaxis

• After the first overt episode, lactulose should be continued indefinitely as secondary prophylaxis. This is a Grade I, strong recommendation from the EASL/AASLD guidelines. [9][10]12
• Rifaximin 550 mg twice daily should be added to lactulose after a second episode or when recurrence occurs despite lactulose alone. A landmark trial showed that rifaximin + lactulose reduced recurrence risk by 58 % (22.1 % vs 45.9 %; NNT = 4) and lowered hospitalization risk (13.6 % vs 22.6 %; NNT = 9). High‑quality evidence supports this benefit. [12][13]14
• Rifaximin monotherapy is not recommended as first‑line treatment for acute overt encephalopathy based on current evidence quality, but it may be used alone for secondary prophylaxis when lactulose is poorly tolerated. [13][14]

Management by Encephalopathy Grade

Grades I–II (Mild‑to‑Moderate)

• Manage on a medical ward with frequent mental‑status checks; ICU care is preferred if deterioration occurs. [8][9]
• Transfer immediately to ICU if level of consciousness declines. [8][9]
• Avoid sedatives (e.g., benzodiazepines, opioids) because they worsen encephalopathy and have delayed clearance in liver failure. [8][15]16
• Perform head CT to exclude intracranial hemorrhage. [15][16]
• Closely monitor glucose, potassium, magnesium, and phosphate levels. [15][16]

Grades III–IV (Severe)

• Admit to ICU and perform immediate endotracheal intubation for airway protection; patients cannot protect their airway and are at high risk of aspiration. [8][9][12][16]
• ICU measures: elevate head of bed to 30°, minimize stimulation and Valsalva‑type maneuvers, use low‑dose propofol only if sedation is absolutely necessary (may reduce cerebral blood flow), deliver lactulose via nasogastric tube if oral intake is impossible, and treat seizures with phenytoin rather than sedatives. [15][16][8][9]

Role of Ammonia Testing

• A normal blood ammonia level should prompt reevaluation for alternative causes of altered mental status; elevated ammonia does not correlate with encephalopathy severity or prognosis and has limited utility beyond excluding hepatic encephalopathy when normal. [11][10]

Liver Transplantation Evaluation

• The first overt episode of hepatic encephalopathy warrants referral to a transplant center for evaluation. Recurrent, intractable overt encephalopathy in the setting of liver failure constitutes a formal indication for liver transplantation. [12][8][9][10]

Critical Pitfalls to Avoid

• Failure to systematically search for precipitating factors (responsible for ≈ 90 % of cases). [9][10]11
• Not titrating lactulose to achieve exactly 2–3 soft stools per day. [8][9]
• Mistaking hepatic encephalopathy for other causes of altered mental status without exclusion of alternative diagnoses. [8][9]
• Omitting secondary prophylaxis after the first episode. [9][10]12
• Relying solely on ammonia levels for diagnosis, staging, or prognosis. 10
• Use of benzodiazepines, which have delayed clearance and exacerbate encephalopathy. [15][16]

Evidence‑Based Management of Overt Hepatic Encephalopathy

Immediate Lactulose Therapy

• Initiate lactulose 25 mL orally every 12 hours and titrate to achieve exactly 2–3 soft stools daily; this regimen resolves overt hepatic encephalopathy in approximately 90 % of patients. 17

Identification and Correction of Precipitating Factors

• Precipitating factors are present in 80–90 % of encephalopathy episodes, and systematic correction alone resolves the condition in about 90 % of cases. 17
• Gastrointestinal bleeding: Screen with history, digital rectal exam, occult blood testing, CBC, and endoscopy when indicated; treat with blood transfusion, endoscopic hemostasis, and vasoactive agents. 17
• Infection: Obtain CBC with differential, CRP, chest radiograph, urinalysis/culture, blood cultures, and diagnostic paracentesis; start empirical broad‑spectrum antibiotics if infection is suspected. 17
• Constipation: Evaluate clinically and with plain abdominal radiography; manage with enemas or osmotic laxatives. 17
• Dehydration: Assess skin turgor, vital signs, and basic metabolic panel; hold diuretics and give intravenous albumin or isotonic fluids as needed. 17
• Electrolyte disturbances: Correct sodium to a target of 140–145 mmol/L together with potassium, magnesium, and phosphate abnormalities. 17
• Renal dysfunction: Monitor BUN, serum creatinine, cystatin C, and electrolytes; adjust nephrotoxic medications and optimize volume status. 17

First‑Line Pharmacologic Therapy

• Rifaximin adjunct: Add rifaximin 550 mg orally twice daily when lactulose alone is insufficient or after a second overt episode; combined therapy reduces recurrence risk by 58 % (22.1 % vs 45.9 %; NNT = 4) and lowers hospitalization risk by 31 % (13.6 % vs 22.6 %; NNT = 9). 17
• Rifaximin should not be used as monotherapy for acute overt encephalopathy; evidence quality does not support it as a first‑line agent. 17

Adjunctive and Second‑Line Therapies

• Intravenous albumin (1.5 g/kg/day) combined with lactulose improves clinical recovery within 10 days (75 % vs 53.3 %; p = 0.03) in patients with grade ≥ 2 encephalopathy. 17
• Oral branched‑chain amino acids (BCAAs) may be employed as adjuncts in patients unresponsive to standard therapy. 17
• Intravenous L‑ornithine L‑aspartate (LOLA) is an alternative/additional option for refractory cases. 17
• Polyethylene glycol (4 L over 4 h) demonstrated superiority to lactulose alone, shortening median time to resolution to 1 day versus 2 days (p = 0.01); further trials are needed. 17

Secondary Prophylaxis (Prevention of Recurrence)

• Continue lactulose indefinitely after the first overt episode; this is a Grade A1 strong recommendation. 17
• Add rifaximin 550 mg twice daily after a second episode or when recurrence occurs despite lactulose alone. 17
• Long‑term rifaximin therapy (> 24 months) is safe and well tolerated. 17
• Without secondary prophylaxis, 50–70 % of patients experience recurrence within one year. 17

Diagnostic Imaging

• Perform a non‑contrast head CT to exclude intracranial hemorrhage, drug intoxication, or other structural causes of altered mental status in all patients with new encephalopathy. 18

Liver Transplantation Considerations

• Recurrent, intractable overt encephalopathy with liver failure constitutes a formal indication for liver transplantation. 17
• Acute liver failure accompanied by hepatic encephalopathy carries a poor prognosis and warrants early transplant evaluation. 17
• Overall survival after an overt encephalopathy episode is 42 % at 1 year and 23 % at 3 years. 17

Safety and Special Considerations

• Long‑term rifaximin use does not increase the risk of Clostridioides difficile infection compared with control groups. 17
• Flumazenil may transiently improve consciousness in severe encephalopathy but does not improve survival and is not recommended as first‑line therapy. 17

Clinical Pitfalls

• Initiating hepatic encephalopathy‑specific therapy before establishing optimal standard care for at least 24–48 hours (unless within a placebo‑controlled trial) is discouraged. [19][18]

All facts are derived from peer‑reviewed evidence with the cited reference IDs indicated in brackets.

Management of Overt Hepatic Encephalopathy

First‑Line Pharmacologic Therapy

• Lactulose 20–30 g (≈25–30 mL) orally 3–4 times daily, titrated to produce exactly 2–3 soft bowel movements per day, is the first‑line treatment for all grades of overt hepatic encephalopathy and should be continued indefinitely after the first episode as secondary prophylaxis. 20
• An equivalent daily dose of lactitol is 67–100 g. 20

Identification and Correction of Precipitating Factors

• Precipitating factors are present in 80–90 % of hepatic encephalopathy episodes; correcting these factors alone resolves the condition in approximately 90 % of cases. 20

• Gastrointestinal bleeding: obtain CBC, digital rectal exam, stool occult blood; perform endoscopy when indicated; treat with blood transfusion, endoscopic hemostasis, and vasoactive medications. [Citation: 20]

• Infection: order CBC with differential, CRP, chest X‑ray, urinalysis/culture, blood cultures, and diagnostic paracentesis; start empiric broad‑spectrum antibiotics immediately if infection is suspected. [Citation: 20]

• Constipation: evaluate clinically and with plain abdominal radiography; manage with enemas or osmotic laxatives. [Citation: 20]

• Dehydration: hold diuretics and administer intravenous albumin or isotonic fluids after clinical assessment. [Citation: 20]

• Renal dysfunction: monitor BUN, serum creatinine, cystatin C, and electrolytes; adjust nephrotoxic medications and optimize volume status. [Citation: 20]

Management of Severe (Grade III–IV) Encephalopathy

• Patients with grade III–IV encephalopathy require immediate ICU admission with endotracheal intubation for airway protection. 20

• ICU positioning: elevate the head of the bed to 30 °. [Citation: 20, 21]

• Lactulose delivery: if oral intake is impossible, administer lactulose via nasogastric tube. [Citation: 20]

• Seizure treatment: use phenytoin rather than benzodiazepines. [Citation: 21]

• Lactulose enema protocol (when oral/NG administration is not feasible): 300 mL lactulose mixed with 700 mL water, administered 3–4 times daily, retained in the intestine for at least 30 minutes until clinical improvement. 20

• Intracranial hypertension: give intravenous mannitol 0.5–1 g/kg as a bolus (repeat once or twice if serum osmolality < 320 mosm/L). [Citation: 21]

Adjunctive and Second‑Line Therapies

• Intravenous albumin 1.5 g/kg/day combined with lactulose improves clinical recovery within 10 days (75 % vs 53.3 %; p = 0.03). 20

• Intravenous L‑ornithine‑L‑aspartate (LOLA) 30 g/day added to lactulose lowers hepatic encephalopathy grade within 1–4 days (odds ratio 2.06–3.04) and shortens time to symptom recovery (1.92 days vs 2.50 days; p = 0.002). 20

• Oral branched‑chain amino acids 0.25 g/kg/day may be used as adjuncts in patients unresponsive to standard therapy. 20

• Combination of rifaximin 550 mg twice daily with lactulose leads to faster recovery (76 % vs 44 % within 10 days; p = 0.004) and shorter hospital stay (5.8 days vs 8.2 days; p = 0.001) compared with lactulose alone. 20

• Neomycin and metronidazole are not recommended for hepatic encephalopathy because of significant adverse effects (intestinal malabsorption, nephro‑/ototoxicity for neomycin; peripheral neuropathy for metronidazole). 20

Guideline Recommendations for Management of Overt Hepatic Encephalopathy

Initial Assessment and Four‑Pronged Approach

• Patients with overt hepatic encephalopathy should receive simultaneous implementation of four steps: (1) stabilize altered consciousness and protect the airway, (2) exclude alternative causes of mental status change, (3) identify and correct precipitating factors (present in 80–90 % of episodes), and (4) start empirical lactulose without delay. 22

Importance of Identifying Precipitating Factors

• Systematic correction of precipitating factors alone resolves hepatic encephalopathy in approximately 90 % of cases. 22

First‑Line Pharmacologic Therapy

• Lactulose is recommended as the first‑line agent for all grades of overt hepatic encephalopathy. 22
• Clinical response to lactulose is achieved in roughly 75 % of treated patients. 22

Adjunctive Therapies

• Oral branched‑chain amino acids (≈ 0.25 g/kg/day) may be added for patients who do not respond adequately to standard therapy. 22

Secondary Prophylaxis (After First Episode)

• Long‑term lactulose therapy is mandatory after the first overt episode; it should be continued indefinitely and titrated to produce 2–3 soft stools daily. This is a Grade I, strong recommendation. 22
• Adding rifaximin 550 mg twice daily after a second episode—or when recurrence occurs despite lactulose—reduces recurrence risk by 58 % (22.1 % vs 45.9 %; NNT = 4) and lowers hospitalization risk by 31 % (13.6 % vs 22.6 %; NNT = 9). 22

Role of Ammonia Testing

• A normal blood ammonia level should prompt clinicians to search for alternative causes of altered mental status. 22
• Elevated ammonia levels do not correlate with encephalopathy severity or prognosis and have limited utility beyond confirming that hepatic encephalopathy is not excluded when the level is normal. 22

Indications for Liver Transplantation Evaluation

• Patients should be evaluated for liver transplantation after the first overt hepatic encephalopathy episode. 22
• Recurrent, intractable overt hepatic encephalopathy in the setting of liver failure constitutes a formal indication for liver transplantation. 22

Prognosis After an Overt Episode

• Overall survival after an overt hepatic encephalopathy episode is 42 % at 1 year and 23 % at 3 years. 22

Evidence‑Based Management of Overt Hepatic Encephalopathy in Adults

Immediate Management

• All adults with overt hepatic encephalopathy should receive an immediate four‑pronged approach: (1) stabilize altered consciousness and protect the airway, (2) exclude alternative causes such as intracranial hemorrhage or infection, (3) identify and correct precipitating factors, and (4) start empirical lactulose without delay. 23

Pharmacologic Therapy – First‑Line

• Continue lactulose indefinitely after the first overt episode as secondary prophylaxis, titrating to achieve 2–3 soft stools per day; this is a Grade I, strong recommendation. 23

Secondary Prophylaxis

• Ongoing lactulose therapy (2–3 soft stools daily) is mandatory after the initial overt episode to prevent recurrence. 23

Advanced/Refractory Therapies

• Intravenous L‑ornithine L‑aspartate (30 g/day) in patients with refractory overt encephalopathy lowers the encephalopathy grade within 1–4 days (odds ratio ≈ 2.0–3.0) and shortens recovery time by ≈ 0.6 days. 23
• Oral branched‑chain amino acids (0.25 g/kg/day) may be added as an adjunct in patients who do not respond adequately to lactulose ± rifaximin. 23

Transplant Evaluation

• Recurrent, intractable overt hepatic encephalopathy with liver failure is a formal indication for evaluation for liver transplantation. 23

Hepatic Encephalopathy: Evidence‑Based Screening, Diagnosis, and Management

1. Screening and Epidemiology

• All individuals with cirrhosis should be screened for hepatic encephalopathy (HE) regardless of liver disease severity, and lactulose therapy (25 mL orally every 12 h, titrated to 2–3 soft stools daily) should be initiated immediately; correcting precipitating factors alone resolves ≈ 90 % of episodes. 24
• Overt HE is present in 30–45 % of cirrhotic patients, with an annual incidence of ~20 %; prevalence rises to ~50 % after transjugular intra‑hepatic portosystemic shunt (TIPS) placement. 24
• Covert (minimal) HE affects > ⅔ of cirrhotic patients, with some studies reporting prevalence up to 85 %. 24

2. Clinical Suspicion and Diagnostic Tools

• Systematic assessment for signs strongly suggestive of overt HE—including asterixis, psychomotor slowing, sleep‑wake inversion, temporospatial disorientation, and impaired consciousness—is recommended. 24
• The animal‑naming test is the preferred bedside tool for detecting covert HE. 24
• Structured interview of the patient and family regarding psychomotor slowing, sleep disturbances, calculation difficulties, and recent loss of routine abilities aids detection of covert HE. 24
• A Critical Flicker Frequency (CFF) value < 38 Hz, when available, indicates covert HE. 24

3. Imaging and Exclusion of Alternative Causes

• Non‑contrast head CT should be performed in every patient with new encephalopathy to rule out intracranial hemorrhage, structural lesions, or other intracranial pathology. 25
• Brain imaging is recommended for all chronic liver disease patients with unexplained neurological dysfunction. 25
• Electroencephalography may reveal patterns that mimic HE in the context of renal failure, hyponatremia, or septic encephalopathy. 25
• Alternative etiologies to investigate include infections, renal dysfunction, electrolyte disturbances (e.g., hyponatremia), intracranial hemorrhage, seizures, psychiatric disorders, and drug‑related effects. 25

4. Pharmacologic Therapy

• First‑line: Lactulose 25 mL orally every 12 h, titrated to produce 2–3 soft stools per day, achieves clinical response in ~75 % of overt HE episodes. (Evidence level not specified in cited source.)
• Second‑line/add‑on: Rifaximin 550 mg orally twice daily is indicated for patients with recurrent episodes despite optimal lactulose therapy or after a second overt episode; it reduces recurrence risk by 58 % (22 % vs 46 %) and hospitalization risk by 31 % (14 % vs 23 %). 25
• Adjunctive agents for refractory cases:
  
  • Oral branched‑chain amino acids (≈ 0.25 g/kg/day) may be added when standard therapy fails. 25

5. Prognosis

• Overall survival after an overt HE episode is 42 % at 1 year and 23 % at 3 years. 24

6. Discharge Planning and Follow‑Up

• Prior to discharge, clinicians should confirm the patient’s neurological status and delineate which deficits are attributable to HE versus other comorbidities. 25
• Caregivers should be educated about medication effects (lactulose, rifaximin), potential side‑effects (e.g., diarrhea), and the critical importance of adherence to lactulose therapy. 25
• Early warning signs of recurrent HE—such as sleep disturbances, confusion, and asterixis—should be highlighted to patients and families. 25
• A structured outpatient follow‑up plan should include:
  
  • Review and adjustment of HE‑targeted therapy,
  • Monitoring of neurological manifestations and gait/fall risk,
  • Ongoing identification and mitigation of precipitating factors,
  • Coordination with primary care and family support services. 25